The Autumn Budget 2026 contains a series of significant announcements designed to strengthen the UK’s position as a global centre for research, development and innovation. From major investments in scientific infrastructure and university collaboration through to reforms of the R&D tax relief regime, the government has signalled a continued commitment to supporting innovation-led growth.
Alongside direct public funding, the Budget also includes substantial private-sector investment commitments in life sciences research and advanced manufacturing, demonstrating continued confidence in the UK’s innovation ecosystem.
Building World-Leading R&D Clusters
A key theme running through the Budget is the government’s desire to develop globally competitive innovation clusters across the UK.
UK Research and Innovation (UKRI) has announced major investments in research infrastructure, including £424 million for the transformation of the John Innes Centre and Sainsbury Laboratory at Norwich Research Park into a world-leading hub for plant and microbial science. The project will deliver new state-of-the-art research and innovation facilities intended to strengthen the UK’s capabilities in agricultural and biological sciences.
The government is also investing more than £85 million into the Offshore Renewable Energy Catapult facility in Blyth. The funding will support development of next-generation wind turbine testing facilities and further establish the North East as a leading centre for clean energy innovation.
Of particular interest for businesses across the North, more than £75 million has been allocated to the CoSTAR network of advanced research facilities, including sites in Yorkshire. The network is intended to provide businesses within the UK’s creative industries with access to cutting-edge R&D capabilities and specialist facilities that might otherwise be beyond their reach, helping support innovation, productivity and commercial growth.
Encouraging Research Collaboration
Alongside investment in physical infrastructure, UKRI has committed £19.75 million to support university partnerships that bring together complementary areas of expertise.
The initiative builds on the Cambridge-Manchester Innovation Partnership announced in 2025 and reflects a growing emphasis on collaboration between universities, research institutions and industry. By encouraging organisations to share knowledge, facilities and commercial opportunities, the government hopes to accelerate the journey from research to economic impact.
Major Life Sciences Investments
The life sciences sector continues to be one of the government’s priority areas for growth, with several significant investments supported through government-backed innovation funds.
Convatec has announced plans to invest more than £500 million over the next decade in a new global R&D hub in Manchester. Supported through the Life Sciences Transformational R&D Investment Fund, the facility will strengthen the company’s research, product evaluation and manufacturing capabilities while reinforcing Manchester’s position as a leading life sciences cluster.
Vertex Pharmaceuticals will invest more than £300 million in a new research facility in Oxford, focused on developing transformative medicines for patients with serious diseases. The investment is also supported through the Life Sciences Transformational R&D Investment Fund and further enhances the UK’s standing as a destination for pharmaceutical research and innovation.
Meanwhile, Kindeva will invest £200 million in Loughborough to expand manufacturing capacity for respiratory medicines, supported through the Life Sciences Innovative Manufacturing Fund. The project illustrates the government’s intention to support not only discovery and development, but also advanced manufacturing capability within the UK.
Positive Changes for R&D Tax Relief Claimants
Alongside investment announcements, the government has unveiled measures intended to simplify the R&D tax relief process.
Most notably, the R&D Claim Notification Form will be abolished from 1 April 2027, removing a compliance requirement that many businesses and advisers have found burdensome since its introduction. In addition, the Additional Information Form is set to be simplified from autumn 2027.
While the government has continued to focus on protecting the integrity of the R&D tax relief regime, these changes suggest a recognition that genuine claimants will benefit from a simpler and more proportionate claims process.
A Clear Direction of Travel
Taken together, the announcements provide a clear indication of the government’s innovation strategy. Rather than relying solely on tax incentives, the Budget combines direct investment in research infrastructure, university collaboration, sector-specific funding and private-sector partnerships to strengthen the UK’s innovation landscape.
For businesses undertaking research and development activities, the message is encouraging. Continued investment in research capability, support for innovation clusters and steps to simplify the R&D tax relief regime all point towards a policy environment that remains firmly focused on encouraging innovation, commercialisation and long-term economic growth.
This material is for informational purposes only and should not be relied upon as professional advice.
